• Adoptive transfer of T cells transduced with tumor-reactive Chimeric Antigen Receptors (CARs) is a promising strategy for cancer immunotherapy. (biomedcentral.com)
  • A chimeric antigen receptor (CAR) construct was also shown to be integrated in up to 60 percent of T cells. (businesswire.com)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing treatment modality. (medscape.com)
  • Chimeric antigen receptors (CARs) are synthetic proteins expressed on the surface of T cells. (medscape.com)
  • ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (drugs.com)
  • Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 antibody. (pharmiweb.com)
  • Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy, formerly identified as JNJ-4528 in the U.S. and Europe and LCAR-B38M CAR-T cells in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in earlier lines of treatment. (pharmiweb.com)
  • Now we have game-changing T-cell-redirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies," he explained. (onclive.com)
  • NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. (tmcnet.com)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • Elranatamab is an antibody that binds to both CD3 on T-cells and B-cell maturation antigen (BCMA), which are expressed on the surface of multiple myeloma cells. (medscape.com)
  • Of note, previous treatment with a B-cell maturation antigen (BCMA)-targeted therapy was not allowed in this group of patients. (targetedonc.com)
  • Long-term follow-up from MAJESTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) X CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). (targetedonc.com)
  • Iberdomide demonstrated response rates of approximately 30% as monotherapy in heavily pretreated patients who are triple-class or B-cell maturation antigen refractory. (oncpracticemanagement.com)
  • Received B-cell maturation antigen (BCMA)-targeted therapy. (survivornet.com)
  • Participant has previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or B-cell maturation antigen targeted therapy. (who.int)
  • After cloning the antibody genes into an expression vector, this is then transfected into an appropriate host cell line for antibody expression. (cellsignal.com)
  • Mammalian cell lines are most commonly used for recombinant antibody production, although cell lines of bacterial, yeast, or insect origin are also suitable. (cellsignal.com)
  • The CD38 molecule, with its high and homogenous expression on Multiple Myeloma (MM) cells, appears a suitable target for antibody therapy. (biomedcentral.com)
  • Examples of preparative CSC enrichment from human cancer cell lines using anti-CD44 v9 antibody RV3 (Cat. (bio-connect.nl)
  • The figure below compares the sphere formation ability of CD44 v9-High and CD44 v9-Low cell populations sorted from a human prostate cancer cell line (PC-3) using anti-human CD44 v9 antibody RV3 (Cat. (bio-connect.nl)
  • Janssen will present the results from the Phase 1 and 2 MajesTEC-1 ( Abstract #896 ) studies evaluating teclistamab (BCMAxCD3), an investigational, off-the-shelf, T-cell redirecting bispecific antibody in heavily pre-treated patients with multiple myeloma. (jnj.com)
  • Updated results from the Phase 1 MonumenTAL-1 ( Abstract #158 ) study, evaluating talquetamab (GPRC5DxCD3) - an investigational, off-the-shelf, T-cell redirecting bispecific antibody and the first directed at this novel target for heavily pre-treated patients with multiple myeloma - will be featured in an oral presentation. (jnj.com)
  • 4-9 Patients with relapsed or refractory multiple myeloma that have been exposed to all three major drug classes (triple-class exposed), including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, tend to demonstrate poor clinical outcomes with very low response rates (20% to 30%), short duration of response (2 to 4 months) and poor survival. (drugs.com)
  • Elranatamab is indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (medscape.com)
  • It is a bispecific humanized monoclonal antibody against CD3, a T-cell surface antigen, and GPRC5D (human G-protein coupled receptor family C group 5 member D), a tumor-associated antigen with potential antineoplastic activity. (medscape.com)
  • The following product was used in this experiment: CD38 Monoclonal Antibody (90), eFluor™ 450, eBioscience™ from Thermo Fisher Scientific, catalog # 48-0381-82, RRID AB_11218302. (thermofisher.com)
  • Description: The 90 monoclonal antibody reacts with the mouse CD38 molecule, an ~42 kDa type II transmembrane protein. (thermofisher.com)
  • A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. (thermofisher.com)
  • 1 2 Cell surface antigens CD38 and CD138 can be used to distinguish normal cells from clonal plasma cells, but more extensive use of immunophenotyping has been limited by a lack of universally accepted markers of MM. 3-5 Once diagnosed, the current standard-of-care for MM includes immunomodulatory drugs, proteasome inhibitors, steroids, and antibody therapies. (bmj.com)
  • Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity. (uci.edu)
  • This expanded access protocol will provide access to elranatamab until it becomes commercially available to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option. (uci.edu)
  • The capacity to secret IgA ex vivo suggests that CXCR5-CD19low B cells are antibody secreting cells which was further supported by the finding of elevated transcriptional expression of PRDM1, XBP-1 and IRF4, transcription factors known to regulate plasmablasts (PB) differentiation. (bmj.com)
  • Conclusions Summing up, besides bimodal expression of CD27 the subset of CXCR5- CD19low B cells shared various characteristics with PBs such as phenotype and functionality like antibody secretion and reduced BCR responsiveness. (bmj.com)
  • The efficacy of a therapeutic antibody depends on the Fab fragment and its binding activity to the target antigen, but also depends on the Fc fragment and its interaction with key Fc receptors.Therefore, candidates must be tested against a panel of receptors during antibody engineering. (acrobiosystems.com)
  • Researchers analyzed data from 165 patients with multiple myeloma who received 3 or more prior lines of therapy including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. (targetedonc.com)
  • All patients treated with NXC-201 were triple-class refractory (to at least 1 immunomodulatory drug, 1 proteasome inhibitor and 1 anti-CD38 antibody). (tmcnet.com)
  • Must have received at least 3 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody. (survivornet.com)
  • The FLEX-NK TM multifunctional engager antibody CYT-338 directed against NKp46 and CD38 demonstrated in vitro activity against multiple myeloma tumor targets. (biospace.com)
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. (biospace.com)
  • Virus-specific antibody responses correlated with protection from encephalitis in all mouse strains, suggesting that Tfh-B cell interactions modulate clinical outcome in this model. (cdc.gov)
  • In an effort to bridge this gap, we evaluated cryopreserved PBMCs from 4 patients who survived Ebola virus disease (EVD) using an established mass cytometry antibody panel to characterize various cell populations during both the acute and convalescent phases. (cdc.gov)
  • Participant must have received 4 to 6 cycles of induction therapy, which must contain at a minimum an immunomodulatory drugs (IMiD) and a proteasome inhibitor (PI) (with or without anti-CD38 monoclonal antibody) and must have had a single ASCT 80 to 120 days prior to consent. (who.int)
  • Moreover, BCMA plays an essential role in regulating B cell maturation and differentiation into plasma cells. (biomedcentral.com)
  • CD38 is expressed at increasingly higher levels on B cells at each stage of B-cell differentiation, and is then down-regulated on germinal center B cells and mature plasma cells. (thermofisher.com)
  • CD38, a counter-receptor for CD31, is an ectoenzyme with cyclase and hydrolase enzymatic activity and is speculated to play a role in lymphocyte activation and differentiation. (thermofisher.com)
  • CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. (thermofisher.com)
  • Human myelopoiesis is an exciting biological model for cellular differentiation since it represents a plastic process where multipotent stem cells gradually limit their differentiation potential, generating different precursor cells which finally evolve into distinct terminally differentiated cells. (biomedcentral.com)
  • Explore our series of recombinant neural factors to support the culture and differentiation of nerve cells. (acrobiosystems.com)
  • The focus of this review is to highlight the role of statins in modulating the function and differentiation of various blood cells. (archivesofmedicalscience.com)
  • Transcription factors (TFs) are critical for B-cell differentiation, affecting gene expression both by repres- sion and transcriptional activation. (lu.se)
  • In this study, highly purified, flow-cytometry sorted, classified in relation to normal B-cell differentiation [1]. (lu.se)
  • The cells of origin in most patients with CLL are clonal B cells arrested in the B-cell differentiation pathway, intermediate between pre-B cells and mature B cells. (medscape.com)
  • Traditional polyclonal and monoclonal antibodies are the product of normal B cell development and genetic recombination. (cellsignal.com)
  • While polyclonal antibodies are secreted by many different B cell clones and recognize multiple antigenic epitopes, monoclonals originate from a single B cell clone and are specific for just one epitope. (cellsignal.com)
  • Where polyclonal antibodies are purified directly from the serum of the immunized host, and monoclonals are purified from either hybridoma-derived tissue culture supernatant or ascites, recombinant antibodies are instead purified from the tissue culture supernatants of transfected host cell lines. (cellsignal.com)
  • We generated three retroviral CAR constructs based on huCD38 antibodies, CD3ζ and 4-1BB signaling domains and transduced them into T cells of healthy donors and MM patients to test the in vitro and in vivo efficacy. (biomedcentral.com)
  • These highly specific CD44v monoclonal antibodies are highly recommended for measuring CD44v expression by flow cytometry and for enrichment of CSC populations by cell sorting. (bio-connect.nl)
  • These man-made antibodies may help attack proteins on the surface of multiple myeloid cells. (healthline.com)
  • Mouse anti-human CD45-FITC (Clone 2D1, Cat No. 347463), Mouse Anti-human CD34-PE [Clone 8G12 (also known as HPCA2), Cat No. 348057], Mouse anti-human CD38-PE-Cy™5 (Clone HIT2, Cat No. 555461) and appropriated isotype control antibodies were purchased from BD Biosciences (San Diego, CA, USA). (researchsquare.com)
  • These anti-CD38 monoclonal antibodies will be blockbuster drugs and an important component of multiple myeloma treatment. (ascopost.com)
  • An investigational class of agents in multiple myeloma, the anti-CD38 monoclonal antibodies, could be the next blockbusters in this malignancy, myeloma experts predicted at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. (ascopost.com)
  • Anti-CD38 antibodies target multiple myeloma cells by binding to the CD38 antigen expressed on the cell surface and then signaling the patient's immune system to attack the tumor. (ascopost.com)
  • These anti-CD38 monoclonal antibodies, I believe, will be blockbuster drugs and an important component of multiple myeloma treatment," he predicted. (ascopost.com)
  • Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e. identification of myelomas), and as a marker for activated B and T cells. (thermofisher.com)
  • To check the subset for its capability of secreting antibodies, cell cultures were performed and soluble immunoglobulins were detected using a bead-based flow cytometry assay. (bmj.com)
  • Cytovia is the first company to combine its own iPSC-derived natural killer (iNK) cells and multispecific, NK cell-engaging antibodies and is building a pipeline that encompasses both hematological malignancies and solid tumors. (biospace.com)
  • Human CD38, a surface molecule expressed by immature and activated T and B lymphocytes, has been characterized as a molecule transducing activation and proliferation signals, and intervening in adhesion to endothelium via its ligand CD31. (nih.gov)
  • CD31 is the ligand of CD38. (biolegend.com)
  • CD38 is a type II transmembrane glycoprotein and the receptor of CD31. (cusabio.com)
  • The combination of CD38 and CD31 plays an important role in cell migration and receptor-mediated adhesion. (cusabio.com)
  • CD31 is a 130-140 kD glycoprotein, also known as platelet endothelial cell adhesion molecule (PECAM-1), EndoCAM, and gpIIa. (biolegend.com)
  • The primary ligands for CD31 have been reported to be CD38 and the vitronectin receptor (α v β 3 integrin, CD51/CD61). (biolegend.com)
  • CD38 is a 45 kD type II transmembrane glycoprotein also known as T10. (biolegend.com)
  • These data support further development of CYT-338 as a therapeutic for targeting CD38 expressing multiple myeloma cells. (biospace.com)
  • BCMA, a member of the tumor necrosis factor (TNF) superfamily, is exclusively expressed in a subpopulation of B cells, normal plasma cells, and malignant plasma cells. (biomedcentral.com)
  • BCMA is not present in other hematological cells like hematopoietic stem cells or other tissues. (biomedcentral.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
  • 1 As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells. (drugs.com)
  • Bristol Myers Squibb is now the only company with two approved CAR T cell therapies with distinct targets of CD19 and BCMA. (drugs.com)
  • Now, with the approval of ide-celas the first anti-BCMA CAR T cell therapy, we are excited to finally be able to offer patients a new, effective personalized treatment option that is delivered through a single infusion. (drugs.com)
  • This results in cross-linking of T-cells and myeloma cells and induces a potent cytotoxic T-lymphocyte response against BCMA-expressing cells. (medscape.com)
  • LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And Drug Administration ("FDA") approved BCMA CAR-T Cell therapies. (tmcnet.com)
  • The title of the editorial is, "Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma," published in Haematologica Early View, available at www.nexcella.com/publications . (tmcnet.com)
  • We investigated the effects of monocyte-activating stimuli (IFN-gamma, IL-2, LPS, TNF-alpha, and GM-CSF) on the expression and function of CD38, starting from the observation that human monocytes and the derived lines U937, THP-1, and Mono-Mac-6 bear the molecule on their surface. (nih.gov)
  • Bst1 is a stromal cell line-derived glycosylphosphatidylinositol-anchored molecule that facilitates pre-B-cell growth. (wikipedia.org)
  • My laboratory has particular expertise in preclinical evaluation of small molecule inhibitors and CAR T cells in ALL and AML patient-derived xenograft models, as well as in phosphosignaling analyses and measurement of patients' molecular responses to targeted inhibitors. (upenn.edu)
  • These initial results encouraged us to undertake preclinical investigations with immunotoxins directed against the B-cell restricted CD19 antigen for B-lymphoid tumors and against the CD38 molecule for multiple myeloma. (atsbio.com)
  • Systemic treatments, such as targeted therapies may be selected if cancer cells are present in multiple areas of your body. (healthline.com)
  • When used in combination with other therapies, these drugs may help treat myeloid cells, according to in-vivo studies . (healthline.com)
  • You may be a candidate for a bone marrow transplant (also known as a stem cell transplant) when other therapies prove ineffective. (healthline.com)
  • Today's approval underscores our commitment to deliver innovative therapies for patients with plasma cell diseases. (biospace.com)
  • The development of CAR T therapies and other genetically engineered cell therapies in recent years has resulted in significant benefits for patients, yet there remains a large unmet need for gene editing systems that can be used to develop novel immunotherapy approaches to treat blood cancers," said Brian C. Thomas, PhD, CEO and Co-Founder of Metagenomi. (businesswire.com)
  • During ASH 2021, Janssen will present data that represents its multipronged approach to treating multiple myeloma in both the frontline and relapsed or refractory settings through the development of cell and biologic therapies. (jnj.com)
  • CAR T cell therapies have shown transformational potential for the treatment of hematologic malignancies, and we, with our partners at bluebird bio, are proud to bring the first CAR T cell therapy to appropriate triple-class exposed patients with relapsed or refractory multiple myeloma, offering the chance for durable response," said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb. (drugs.com)
  • As our second FDA-approved CAR T cell therapy, Abecma underscores our commitment to deliver on the promise of cell therapies for patients who are battling aggressive and advanced blood cancers with limited effective treatment options. (drugs.com)
  • A better understanding of the MM cell surface proteome could facilitate development of new directed therapies and assist in stratification and monitoring of patient outcomes. (bmj.com)
  • After his disease went into remission again, this patient has now received 2 different T-cell-redirection therapies when those remissions ended. (onclive.com)
  • T-cell-redirection therapies are now giving anywhere from 60% to 100% response rates that are lasting upward of 9 months to we don't even know how long, because they're so durable. (onclive.com)
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. (biospace.com)
  • Evaluation of Mycobacterium tuberculosis specific antigen-stimulated CD27 - CD38 + IFN-γ + CD4 + T cells for discrimination of active tuberculosis. (bvsalud.org)
  • Also in a xenotransplant model, i.v. injected CD38-CAR T cells were effective against MM tumors growing in a human bone marrow-like microenvironment, thus demonstrating their ability to properly migrate and infiltrate into the tumor niche to lyse malignant cells. (biomedcentral.com)
  • Cancer stem cells (CSCs) are defined as a small, self-renewing cell population within a tumor that can give rise to all other tumor cell types found within that tumor. (bio-connect.nl)
  • Recently however, the ability to enrich and characterize CSC from several tumor types based on the expression of cell surface marker phenotypes is leading to significant progress in defining the nature and roles of CSCs in tumor formation, tumor plasticity, tumor recurrence, and tumor metastasis. (bio-connect.nl)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Next, we developed targeted MS assays, and applied these to cell lines and primary patient samples to refine the list of candidate tumor markers. (bmj.com)
  • Cytovia's GPC3-directed NK-engager in combination with iPSC-derived NK cells demonstrated impressive anti-tumor activity in mice that merits clinical development," added Dr. Michael Friedman , a member of Cytovia's Board of Directors. (biospace.com)
  • For the large number of hepatocellular cancer patients who currently have such limited, poor clinical options, a novel tumor antigen-directed NK engager is needed. (biospace.com)
  • The combination of the FLEX-NK TM and iNK platforms demonstrated greater in vitro and in vivo anti-tumor activity in HCC models than iNK cells alone, with a favorable in vitro cytokine release and immune cell subset safety profile. (biospace.com)
  • However, most GEP studies have typically been performed on whole tissue samples, containing varying degrees of tumor cell content, which results in uncertainties in data analysis. (lu.se)
  • GEP analyses were performed on highly purified, flow-cytometry sorted tumor-cells from eight subgroups of BCLs. (lu.se)
  • This enabled identification of TFs that can be uniquely associated to the tumor cells of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia (HCL), and mantle cell lymphoma (MCL). (lu.se)
  • Immunotherapy consists of drugs that modulate your immune system to fight cancer cells, and is considered the future of multiple myeloma cancer treatment. (healthline.com)
  • This type of immunotherapy relies on T-cells taken from your own blood where they are then genetically modified in a lab before being placed back into your body. (healthline.com)
  • Novel gene editing systems were deployed in NK cells to disrupt CD38 - a cell surface immune modulator that can be targeted in the development of cancer immunotherapy - and to integrate a CAR construct that led to robust CAR-directed cellular cytotoxicity. (businesswire.com)
  • Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)
  • Abecma will be manufactured for each individual patient using the patient's own T cells at Bristol Myers Squibb's state-of-the-art cellular immunotherapy manufacturing facility in Summit, New Jersey. (drugs.com)
  • Designer T and NK cells are a modality within immunotherapy that manipulates receptor-ligand interactions to enhance cells of the immune system to destroy cancer more effectively. (encyclopedia.pub)
  • They also lysed primary malignant cells from acute myeloid leukemia, and multi-drug resistant MM patients. (biomedcentral.com)
  • Although CD38-CAR T cells lysed CD38 + monocytes, NK cells, CD34 + cells and to a lesser extent CD38 + T and B cells, they did not hamper the outgrowth progenitor cells into various myeloid lineages. (biomedcentral.com)
  • To identify regulators of primitive chronic myeloid leukemia (CML) cells, we performed a high-content cytokine screen using primary CD34 + CD38 low chronic phase CML cells. (haematologica.org)
  • Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by an acquired 9;22-chromosomal translocation in a hematopoietic stem cell (HSC) resulting in the expression of the BCR-ABL1 fusion protein. (haematologica.org)
  • Leukemia stem cells (LSCs) in acute myeloid leukemia (AML) played important roles in development of leukemia, chemotherapeutic drug resistance, and disease relapse and progression. (researchsquare.com)
  • Acute myeloid leukemia (AML) is generally regarded as a stem cell disease, and it originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity [ 1 , 2 ]. (researchsquare.com)
  • On the surface of lymphoid cells, myeloid cells and other non-hematopoietic tissue cells, the expression of CD38 shows is lower, but on the surface of malignant plasma cells such as myeloma cells, CD38 shows high expression. (cusabio.com)
  • These cells secrete immune inhibitory growth factors and cytokines, including vascular endothelial growth factor (VEGF), which is primarily produced by microglia, myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages (TAMs). (encyclopedia.pub)
  • Unsupervised analysis of cell abundance demonstrated acute declines in monocytic, NK, and T cell populations, but some populations, many of myeloid origin, increased in abundance during the acute phase, suggesting emergency hematopoiesis. (cdc.gov)
  • The product was purified to obtain the recombinant human CD38 protein carrying C-terminal hFc tag. (cusabio.com)
  • Bst1 (Bone marrow stromal cell antigen 1, ADP-ribosyl cyclase 2, CD157) is an enzyme that in humans is encoded by the BST1 gene. (wikipedia.org)
  • BST1 expression is enhanced in bone marrow stromal cell lines derived from patients with rheumatoid arthritis. (wikipedia.org)
  • Bone marrow is a soft tissue inside your bone that creates blood-forming cells. (healthline.com)
  • 6 AL amyloidosis is a life-threatening blood cell disorder that occurs when blood plasma cells in the bone marrow produce amyloid deposits, which build up in vital organs and eventually cause organ deterioration. (biospace.com)
  • Aberrantly expressed cytokines in the bone marrow (BM) niche are increasingly recognized as critical mediators of survival and expansion of leukemic stem cells. (haematologica.org)
  • 2 1 There is growing evidence to suggest that primitive CML cells affect the bone marrow (BM) niche, contributing to deregulated cytokine levels. (haematologica.org)
  • Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
  • We examined the CD45 dim CD34 + CD38 - CD133 + cells on bone marrow samples of hematologic malignancies and healthy controls using four-color flow cytometry experiments. (researchsquare.com)
  • Interestingly, the CD45 dim CD34 + CD38 - CD133 + cells were highly expressed in bone marrow of patients with AML compared to that of healthy controls (HC). (researchsquare.com)
  • In this study, we focused on measuring LSCs easily in the bone marrow cells from AML patients by developing a four-color flow cytometric analysis. (researchsquare.com)
  • Histopathology of the right tibial lesion was reviewed at IHHN, revealing sheets and aggregates of neoplastic cells replacing bone marrow interspersed with sclerotic bony fragments. (hindawi.com)
  • Multiple myeloma, an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. (pharmiweb.com)
  • Background Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow. (bmj.com)
  • Diagnosis of MM is based on morphological features, imaging studies, analysis of myeloma cell-produced proteins, and testing of the blood, urine, and bone marrow (BM). (bmj.com)
  • While several lines of evidence suggest a protective role of T cells against disease associated with Dengue virus (DENV) infection, their potential contribution to immunopathology in the acute phase of DENV infection remains controversial, and it has been hypothesized that the more severe form of the disease (dengue hemorrhagic fever, DHF) is associated with altered T cell responses. (mdpi.com)
  • This is clearly shown in Figure 2, where increasing concentrations of two immunotoxins: anti-CD19 (BU12-Saporin) and anti-CD38 (OKT10-SAP) show decreasing protein synthesis levels in a target CD19+ CD38+ pediatric acute lymphoblastic leukaemia (ALL) cell line. (atsbio.com)
  • Figure 2 Protein synthesis inhibition in the CD19+/CD38+ acute lymphoblastic cell line, NALM-6, following 48h exposure to increasing concentrations of BU12-Saporin, OKT10-SAP, a combination of both immunotoxins, or saporin alone. (atsbio.com)
  • Despite cell losses during the acute phase, upregulation of Ki-67 correlated with recovery of cell populations over time. (cdc.gov)
  • We investigated baseline surface marker expression and Syk phosphorylation kinetics upon B cell receptor (BCR) stimulation of peripheral B cells and specifically the CXCR5-CD19low subset using flow cytometry. (bmj.com)
  • The CDC guidelines concerning CD4+ T-cell determinations (33) were first published in the MMWR in 1992 to provide laboratorians with the most complete information about how to measure CD4+ T-lymphocytes in blood from HIV-infected persons by using flow cytometry. (cdc.gov)
  • Flow cytometry is an important methodology for the diagnosis of chronic B-cell lymphoproliferative diseases (B-CLPD), however, sometimes the cytometrist does not find sufficient elements for the exact definition of the pathological entity involved. (bvsalud.org)
  • The results emphasize that even though flow cytometry is important for the characterization of B-CLPD, sometimes the cytometrist needs to include the category "other chronic B-cell lymphoproliferative diseases not classified by flow cytometry" in the report to induce the prescriber to request additional complementary exams. (bvsalud.org)
  • Immunoprecipitation of CD38 protein from mouse spleen tissue extracts. (cellsignal.com)
  • 1 DARZALEX FASPRO ® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the deterioration of vital organs, most notably the heart, kidneys and liver. (biospace.com)
  • 1 The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase and triggers a cascade of aberrant downstream signaling pathways leading to clonal outgrowth of CML cells and subsequent disease manifestation. (haematologica.org)
  • it recognizes a specific protein on the surface of malignant cells (eg, CD19 on B-cells). (medscape.com)
  • A poignant reminder here was the disastrous peripheral nerve damage experienced by women with breast cancer treated with a ricin A chain-based immunotoxin which unexpectedly also targeted nervous tissue.4 The most sensitive in vitro method for determining the selective cytotoxic potency of saporin-based immunotoxins is by measuring their ability to selectively inhibit protein synthesis in antigen-expressing cell lines in a dose-dependent manner. (atsbio.com)
  • The IC50 is shown as the point on the x-axis intercept representing the concentration of ITthat inhibits protein synthesis in the target cell line by 50% relative to untreated control cells. (atsbio.com)
  • This CD38 protein migrated along the gel to a band of about 58-90 kDa molecular weight. (cusabio.com)
  • CD38 is a gene providing instruction of making a protein named ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (also abbreviated as ADPRC1 or CD38) in human and belongs to ADP-ribosyl cyclase family. (cusabio.com)
  • Neural factors are a class of protein molecules with neurotrophic activity that can promote the survival and regeneration of nerve cells. (acrobiosystems.com)
  • Surface receptors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and nuclear transcription factors attenuate T cell responses, where CTLA-4 competes with CD28 for binding to CD80/86, resulting in inhibitory downstream signalling [ 6 ] . (encyclopedia.pub)
  • The proteasome pathway is an enzyme complex existing in all cells, which degrades ubiquitinated proteins that control the cell cycle and cellular processes and maintains cellular homeostasis. (medscape.com)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Moreover, the CD34 + CD38 - progenitor cells expressed variable amounts of the target receptor CD33, CD133 and c-kit (CD117) [ 20 ]. (researchsquare.com)
  • Kochenderfer et al described dramatic regression of the lymphoma after infusion of CAR T cells engineered to target CD19. (medscape.com)
  • Plasmablast-like Phenotype Among Antigen-Experienced CXCR5-CD19(low) B Cells in Systemic Lupus Erythematosus. (bmj.com)
  • Moreover, CD44 is reported as cell surface marker for cancer stem cells (CSCs) derived from solid tumors including breast, prostate, colon, head and neck and pancreatic cancer. (bio-connect.nl)
  • B-cell lymphomas (BCLs) constitute a diverse set of tially identify new functional, diagnostic, and therapeutic tumors, both morphologically and clinically, that are mainly targets. (lu.se)
  • iNK cells expressed a favorable combination of multiple activation and few inhibitory receptors that corresponded to more potent cytolytic activity against HCC targets. (biospace.com)
  • Additionally, the high levels of the CD45 dim CD34 + CD38 - CD133 + cells in AML patients were an independently significant poor risk factor for overall survival and event free survivals. (researchsquare.com)
  • Therefore, our results suggest that CD45 dim CD34 + CD38 - CD133 + cells in AML might have the potential of leukemia stem cells. (researchsquare.com)
  • For examples, Rhenen et al showed that a high percentage of CD34 + CD38 - stem cells at diagnosis significantly correlated with a high minimal residual disease frequency and subsequently to relapse especially after the third course of chemotherapy in AML patients. (researchsquare.com)
  • Furthermore, it was developed using the basic platform of the CD34 + CD38 - markers, but applying more advanced antigens such as CD45 dim and CD133. (researchsquare.com)
  • Treatment with IFN-gamma produced a dose- and time-dependent up-regulation of CD38 in monocytes and monocytic lines, which was paralleled by increased ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase activities. (nih.gov)
  • These findings identify IFN-gamma as a modulator of monocytic CD38 expression and indicate that CD38 plays a specific role in the activation and adhesion processes performed by monocytes. (nih.gov)
  • It is a member of the Ig superfamily, expressed on endothelial cells, platelets, granulocytes, monocytes/macrophages, dendritic cells, and T and B cell subsets, and is critical for cell-to-cell interactions. (biolegend.com)
  • By functioning as both a cyclase and a hydrolase, CD38 mediates lymphocyte activation, adhesion, and the metabolism of cADPR and NAADP. (biolegend.com)
  • A prototype of mammalian ADPR-cyclases is a lymphocyte antigen CD38. (elsevierpure.com)
  • PD-1 is an immunoinhibitory receptor that stymies lymphocyte proliferation and cytokine secretion when bound to its membrane-bound or secreted ligands, PD-L1 or PD-L2, expressed by both immune and tumour cells [ 7 ] . (encyclopedia.pub)
  • With this feature, CD38 has become a popular target for the treatment of multiple myeloma (MM). (cusabio.com)
  • Multiple Myeloma - 90% overall response rate (59% complete responses) for NXC-201 at the therapeutic dose in an ongoing 42-Patient Phase 1 expansion trial (Haematologica https://doi.org/10.3324/haematol.2022.281628 , 5th European CAR-T cell meeting https://www.nexcella.com/publications/ ) in relapsed/refractory multiple myeloma. (tmcnet.com)
  • AL Amyloidosis - 100% organ response rate (cardiac, renal, liver), 100% complete hematologic responses (MRD negativity 10 -5 ), for NXC-201 in 8 relapsed/refractory AL Amyloidosis patients, of which the initial cohort was presented at the 5th European CAR-T cell meeting https://ww.nexcella.com/publications/ , and published in Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 . (tmcnet.com)
  • These preclinical proof of concept studies with CYT-303 alone or in combination with iNK cells in HCC warrant clinical development. (biospace.com)
  • As cells undergo oncogenesis, neoantigens are released and captured on major histocompatibility complex (MHC)/ human leukocyte antigen (HLA) of dendritic cells (DCs) that subsequently mature and migrate to central lymphoid organs. (encyclopedia.pub)
  • Furthermore, dendritic cells exposed to NETotic neutrophils trigger ANCA autoimmunity in mice (25), and NET debris has been histologically identified in the microvasculature of patients with small vessel vasculitis (26), suggesting a pathogenic nature of NETs in AAV. (biotechnologyconsultinggroup.com)
  • Examples include daratumumab (Darzalex) and isatuximab (Sarclisa) for CD38 proteins, or elotuzumab ( Empliciti ) for SLAMF7 proteins. (healthline.com)
  • These age-related immunological changes resemble those seen during treated HIV-1 infection and include high levels of soluble inflammatory proteins, high levels of monocyte and T cell activation, T cell exhaustion and senescence, and low levels of naïve T cells ( 14 - 25 ). (frontiersin.org)
  • 2 Bcl-2 (B-cell lymphoma-2) family of antiapoptotic (bcl-2, bcl-xl, bcl-w and mcl-1) and proapoptotic (bax, bak and bok) proteins are critical regulators of apoptosis in CLL. (haematologica.org)
  • MS-based validation using primary specimens detected 30 proteins with significantly higher abundance in patient MM cells than controls. (bmj.com)
  • Nine of these proteins were identified as potential immunotherapeutic targets, including five that were validated by FCM, confirming their expression on the cell surface of primary MM patient cells. (bmj.com)
  • The larger design of the CELMoD agents allows for tighter binding to the cereblon E3 ligase complex, resulting in rapid degradation of a specific set of proteins and ultimately leads to direct apoptosis of myeloma cells. (oncpracticemanagement.com)
  • It is closely associated with B cell-activating factor of the TNF family (BAFF) receptor, transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) [ 14 ]. (biomedcentral.com)
  • There is an urgent need for awareness and treatment options to help in the fight against this serious blood cell disorder," said Raymond L. Comenzo , M.D., Director, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, and ANDROMEDA study investigator. (biospace.com)
  • Today's submission is an encouraging step in our mission to provide a potentially transformative cell therapy option to patients with multiple myeloma," said Ying Huang, PhD, CEO and CFO of Legend Biotech. (pharmiweb.com)
  • Motixafortide is indicated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. (medscape.com)
  • The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT). (uci.edu)
  • The expected therapeutic dose of NXC-201 (800 million CAR+T cells) has already been established as the recommended Phase 2 dose (RP2D) for both multiple myeloma and AL amyloidosis. (tmcnet.com)
  • Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). (survivornet.com)
  • The data presented at AACR supports the advancement of our lead GPC3-targeting hepatocellular carcinoma (HCC) program towards clinical trials and our differentiated CD38-targeting multiple myeloma program to IND-enabling studies. (biospace.com)
  • Participants aged =18 with Newly Diagnosed Multiple Myeloma (NDMM) who has received induction therapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), without subsequent consolidation or maintenance. (who.int)
  • Initially considered a variation of diffuse large B-cell lymphoma (DLBCL), PBL was later classified as a distinctive mature B-cell lymphoma and separated from the class of DLBCL by WHO [ 1 ]. (hindawi.com)
  • About 2 to 10% of CLL cases develop into diffuse large B-cell lymphoma (called Richter's transformation). (msdmanuals.com)
  • Subsequently, binding of the CD28 co-stimulatory receptor to the DCs' CD80/86 receptor fully activates the cytotoxic T cells which then migrate to infiltrate the tumour and kill the cells by locally releasing perforin and granzymes [ 2 ] [ 3 ] . (encyclopedia.pub)
  • In addition, activated T cells can express an inducible co-stimulator (iCOS), a surface receptor that is structurally and functionally similar to CD28 and enhances expression of Th2-related interleukin (IL)-10 rather than immune activating IL-2 [ 8 ] . (encyclopedia.pub)
  • These results signify the potential importance of CD38-CAR T cells as therapeutic tools for CD38 + malignancies, including MM, and warrant further safety and efficacy evaluation in appropriate models. (biomedcentral.com)
  • The most obvious candidate disease is cancer and consequently the vast majority of early phase clinical studies with immunotoxins have centered on the treatment of human malignancies with the goal of eliminating cancer cells from the patient's body. (atsbio.com)
  • In addition, this cell population might be a novel therapeutic target for AML. (researchsquare.com)
  • When the same two immunotoxins were used individually in vivo in SCID mice xenografted with the same ALL cell line, they exerted therapeutic activity in line with the data obtained from the in vitro study. (atsbio.com)
  • Our data suggest that CXCR5-CD19low B cells are precursors of PBs and targeting this subset in SLE may have therapeutic value. (bmj.com)
  • Furthermore, we show expression of MSTN by CML mesenchymal stromal cells, and that myostatin propeptide has a direct and instant effect on CML cells, independent of myostatin, by demonstrating binding of myostatin propeptide to the cell surface and increased phosphorylation of STAT5 and SMAD2/3. (haematologica.org)
  • Crosslinking of CD38 on the surface of mature, resting B cells induces B-cell proliferation, which is enhanced by co-signals such as IL-4 and LPS. (thermofisher.com)
  • CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor. (thermofisher.com)
  • Methods In this study, we first used a mass spectrometry (MS)-based discovery-driven cell surface capture (CSC) approach to map the cell surface N -glycoproteome of MM cell lines. (bmj.com)
  • Results We identified 696 MM cell surface N -glycoproteins by CSC, and developed 73 targeted MS detection assays. (bmj.com)
  • Surface marker expression of CD38, CD95 and CD71 and IgA and IgG suggest an activated and antigen experienced phenotype. (bmj.com)
  • CD38 is also a complex ectoenzyme featuring ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase activities, leading to the synthesis and degradation of cADPR, a Ca+-mobilizing agent. (nih.gov)
  • CD157 and CD38 are both members of the ADP-ribosyl cyclase family of enzymes that catalyze the formation of nicotinamide and adenosine diphosphate ribose (ADPR) or cyclic ADP-ribose (cADPR) from NAD+, although CD157 is a much weaker catalyst than CD38. (wikipedia.org)
  • cADPR is required for regulation of Ca22+ in cells. (wikipedia.org)
  • Only CD38 hydrolyzed cADPR to ADPR. (wikipedia.org)
  • Characterization of the compound in a cell-based system revealed that an extracellular calcium-sensing receptor (CaSR)-mediated cADPR production and a later long-lasting increase in intracellular Ca 2+ concentration ([Ca 2+ ] i ) in mouse mesangial cells were inhibited by the pre-treatment with this compound. (elsevierpure.com)
  • In contrast, the compound did not block CD3/TCR-induced cADPR production and the increase of [Ca 2+ ] i in Jurkat T cells, which express CD38 exclusively. (elsevierpure.com)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. (smw.ch)
  • They are generated by immunizing an animal with an antigen to elicit an immune response. (cellsignal.com)
  • Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. (ox.ac.uk)
  • In this study, we have used tetrameric major histocompatibility complex-peptide complexes to directly visualize antigen-specific cluster of differentration (CD)8+ T cells during the primary immune response to Epstein-Barr virus (EBV) infection in humans. (ox.ac.uk)
  • In addition to their efficient lipid-lowering effects, statins exhibit independent so called pleiotropic effects potentially affecting several immune response properties including immune cell activation, migration, cytokine generation, immune metabolism, and survival. (archivesofmedicalscience.com)
  • Whereas the standard isoform of CD44 (CD44 s) is expressed predominantly in hematopoietic cells and normal epithelial cell subsets, CD44v (variant) isoforms contain insertions in the membrane-proximal extracellular region and are highly expressed in epithelial-type carcinomas. (bio-connect.nl)
  • Quizartinib and its active metabolite (AC886) inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. (medscape.com)
  • The T cells also effectively terminate their activation and proliferation as a means of avoiding autoimmunity, resulting in different phenotypes that either further activate Th1 immune responses or suppress via Th2-driven responses. (encyclopedia.pub)
  • Classical monocyte proliferation and CD38 upregulation on plasmacytoid DCs coincided with declining viral load. (cdc.gov)
  • The majority of the antigen-specific cells had an activated/memory phenotype, with expression of human histocompatibility leukocyte antigen (HLA) DR, CD38, and CD45RO, downregulation of CD62 leukocyte (CD62L), and low levels of expression of CD45RA. (ox.ac.uk)
  • This immunosuppressive helper T cell phenotype can be further induced by the zinc-finger transcription factor GATA3, which regulates Th2 cytokine expression [ 9 ] . (encyclopedia.pub)
  • RVFV-specific CD8 T cells were expanded and of a cytotoxic and proliferating phenotype in the liver following infection. (cdc.gov)
  • Immunohistochemical analysis of paraffin-embedded mouse spleen using CD38 (E9F5A) XP ® Rabbit mAb (left) compared to concentration-matched Rabbit (DA1E) mAb IgG XP ® Isotype Control #3900 (right). (cellsignal.com)
  • Confocal immunofluorescent analysis of fixed frozen mouse spleen labeled with CD38 (E9F5A) XP ® Rabbit mAb (left, green). (cellsignal.com)
  • This compound inhibited kidney ADPR-cyclase activity but not CD38, spleen, heart or brain ADPR-cyclase activity in vitro. (elsevierpure.com)
  • RVFV-specific CD4 T cells were identified in the liver and spleen following infection and phenotyped as largely Th1 or Tfh subtypes. (cdc.gov)
  • It is an ADP-ribosyl hydrolase expressed at variable levels on hematopoietic cells and in some non-hematopoietic tissues (such as brain, muscles, and kidney). (biolegend.com)
  • The ability to avoid the consequences of exposure to high levels of ROS is required for cancer cell survival and propagation in vivo . (bio-connect.nl)
  • Their guidance is also based on what they believe will work at your stage, as well as where cancer cells are located. (healthline.com)
  • Chemotherapy is a powerful treatment used to kill cancer cells. (healthline.com)
  • Additionally, a steroid such as prednisone may be prescribed to off-set some chemotherapy side effects while also suppressing inflammation and cancer cell growth. (healthline.com)
  • Radiation uses beams of high energy to shrink malignant cells and stop the growth of cancer. (healthline.com)
  • In approved products, a patient's own T lymphocytes are collected by apheresis and transduced with a gene that encodes for a CAR to direct the T cells against cancer cells. (medscape.com)
  • Once infused, the cells continue to expand in number and bind to cancer cells via the engineered receptor, resulting in immunologic cancer cell death. (medscape.com)
  • Patient's own immune cells are isolated, genetically modified to improve responses against cancer cells, expanded, and subsequently reintroduced into the individual. (encyclopedia.pub)
  • Patrolling leukocytes detect mutated, early transformed cells, deem them sufficiently "non-self" and co-ordinately eliminate them, as predicted by the cancer immunosurveillance concept [ 1 ] . (encyclopedia.pub)
  • The rapidly growing tumour alters the balance of interaction between cancer and immune cells, by outstripping its metabolic resources and shifting to glycolysis [ 15 ] . (encyclopedia.pub)
  • Cancer cells also recruit and alter nearby stromal cells to aid the tumour cells in avoiding immune detection and destruction [ 16 ] [ 17 ] . (encyclopedia.pub)
  • In summary, we identify myostatin propeptide as a novel positive regulator of primitive CML cells and corresponding normal hematopoietic cells. (haematologica.org)
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • SDF-1α and CXCR4 play a role in trafficking and homing of human hematopoietic stem cells to the marrow compartment. (medscape.com)
  • CD157 is a paralog of CD38, both of which are located on chromosome 4 (4p15) in humans. (wikipedia.org)
  • In humans, it is expressed at high levels on plasma cells and activated T and B cells. (biolegend.com)
  • Peripheral blood mononuclear cells from this cohort of individuals were used to map out the viral epitopes targeted by T cells in humans. (cdc.gov)
  • In vitro sphere formation assays are a type of colony formation assay used to evaluate the clonogenic potential of CSCs and other stem cells. (bio-connect.nl)
  • The genetically modified autologous T cells are expanded in vitro at a production facility and then reinfused into the patient. (medscape.com)
  • Our results indicate that IFN-gamma is a strong up-modulator of CD38, and IL-2 increases its expression only modestly. (nih.gov)
  • Irrespective of the donor, CD38-CAR T cells lost CD38 expression, expanded readily and lysed MM and other malignant cell lines in a cell dose-, and CD38-dependent manner. (biomedcentral.com)
  • Hiza H, Hella J, Arbués A, Sasamalo M, Misana V, Fellay J, Gagneux S, Reither K, Portevin D. CD38 expression by antigen-specific CD4 t cells is significantly restored 5 months after treatment initiation independently of sputum bacterial load at the time of tuberculosis diagnosis. (swisstph.ch)
  • Its expression is reported on a subpopulation of thymocytes, mature T cells, and NK cells. (thermofisher.com)
  • Gene expression data from 24 experiments for 8 different cell types of the human myelopoietic lineage were used to generate an integrated myelopoiesis dataset of 9,425 genes, each reliably associated to a unique genomic position and chromosomal coordinate. (biomedcentral.com)
  • For instance, the existence of tissue-specific gene clusters may be related to the efficient activation of gene expression in a particular cell lineage, by genetic and epigenetic mechanisms, or related to the repression of entire chromosomal regions containing genes expressed in a specific cell type, e.g. during the developmental switches leading to different cell lineages [ 25 ]. (biomedcentral.com)
  • After cloning, the expression vector was introduced into the Mammalian cell for expression. (cusabio.com)
  • CUSABIO synthesized the recombinant gene by integrating the C-terminal hFc tag sequence into the targeted gene encoding the 43-300aa of the human CD38. (cusabio.com)
  • Also, these cell populations directly correlated with poor survival [ 2 , 5 ]. (researchsquare.com)
  • After recovery from AIM, the frequency of antigen-specific T cells fell in most donors studied, although populations of antigen-specific cells continued to be easily detectable for at least 3 yr. (ox.ac.uk)
  • CD38 is widely expressed in tissues, whereas CD157 is primarily found in gut and lymphoid tissue. (wikipedia.org)
  • Human peripheral blood lymphocytes were stained with CD38 (clone HIT2) APC/Fire™ 810 (filled histogram) or cells were left unstained (open histogram). (biolegend.com)